The transcriptional interaction between KAT6A and ESR1, along with the high frequency and the critical role of ESR1 mutations in ER+ breast cancer, has prompted researchers to investigate the potential impact of ESR1 mutations on the efficacy of KAT6 inhibitors. This evidence concerns the gene KAT6A and breast carcinoma.